Literature DB >> 8339232

Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial.

R J Packer1, J M Boyett, R A Zimmerman, L B Rorke, A M Kaplan, A L Albright, M T Selch, J L Finlay, G D Hammond, W M Wara.   

Abstract

BACKGROUND: Most children with brain stem gliomas (BSG) die within 18 months of diagnosis. Early experience suggested that hyperfractionated radiation therapy (RT) at a dose of 72 Gy, administered in 1-Gy fractions twice daily, possibly improved disease-free survival for children with BSG.
METHODS: To better characterize the toxicity and possible efficacy of this dose and fractionation of RT, 53 assessable children with diffuse intrinsic or malignant BSG were treated. Survival figures also were combined with outcome in 36 patients treated in a previous pilot study.
RESULTS: An objective response to treatment was observed in 28 of 53 (53%) patients; a partial response occurred in 7. No child died of treatment-related brain necrosis, although 7 of 53 did have intralesional cystic/necrotic changes within 6 weeks of completion of RT. The overall survival rate for patients in the study was 38% (+/- 6.5) at 1 year, 14% (+/- 5.4) at 2 years, and 8% (+/- 6.5) at 3 years. Leptomeningeal dissemination was observed in 4 of 48 (8%) children who had relapses. A greater than 2-month duration of symptoms before diagnosis was related to a better prognosis. There was no statistical association between any other clinical parameter, neuroradiographic finding, or pathologic finding and outcome. Combined with that in 35 patients treated in the pilot study, the survival rate in 88 children was 14% (+/- 5) at 3 years.
CONCLUSIONS: The radiographic response rate is encouraging; however, it cannot be concluded that hyperfractionated RT, at this dose schedule and total dose, is superior to conventional RT.

Entities:  

Mesh:

Year:  1993        PMID: 8339232     DOI: 10.1002/1097-0142(19930815)72:4<1414::aid-cncr2820720442>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium.

Authors:  Tina Young Poussaint; Sridhar Vajapeyam; Kelsey I Ricci; Ashok Panigrahy; Mehmet Kocak; Larry E Kun; James M Boyett; Ian F Pollack; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2015-10-20       Impact factor: 12.300

2.  Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma.

Authors:  Ulrike Löbel; Jan Sedlacik; Noah D Sabin; Mehmet Kocak; Alberto Broniscer; Claudia M Hillenbrand; Zoltán Patay
Journal:  Neuroradiology       Date:  2010-09-28       Impact factor: 2.804

Review 3.  Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy.

Authors:  M T Jennings; M L Freeman; M J Murray
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

4.  Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.

Authors:  Rajni Sethi; Jeffrey Allen; Bernadine Donahue; Matthias Karajannis; Sharon Gardner; Jeffrey Wisoff; Saroj Kunnakkat; Jeena Mathew; David Zagzag; Kia Newman; Ashwatha Narayana
Journal:  J Neurooncol       Date:  2010-07-10       Impact factor: 4.130

5.  Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.

Authors:  Kristin A Bradley; Tianni Zhou; Rene Y McNall-Knapp; Regina I Jakacki; Adam S Levy; Gilbert Vezina; Ian F Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-22       Impact factor: 7.038

6.  Pediatric diffuse intrinsic pontine glioma patients from a single center.

Authors:  Rejin Kebudi; Fatma Betul Cakir; Fulya Yaman Agaoglu; Omer Gorgun; Inci Ayan; Emin Darendeliler
Journal:  Childs Nerv Syst       Date:  2012-12-08       Impact factor: 1.475

7.  Outcome and prognostic factors of childhood diffuse brainstem glioma.

Authors:  Semie Hong; Il Han Kim; Kyu Chang Wang
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

8.  Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.

Authors:  Lindsay B Kilburn; Mehmet Kocak; Franziska Schaedeli Stark; Georgina Meneses-Lorente; Carrie Brownstein; Sazzad Hussain; Murali Chintagumpala; Patrick A Thompson; Sri Gururangan; Anuradha Banerjee; Arnold C Paulino; Larry Kun; James M Boyett; Susan M Blaney
Journal:  Neuro Oncol       Date:  2013-04-16       Impact factor: 12.300

9.  Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience.

Authors:  Stefano Gabriele Vallero; Daniele Bertin; Maria Eleonora Basso; Laura Stefania Pittana; Anna Mussano; Franca Fagioli
Journal:  Childs Nerv Syst       Date:  2014-01-14       Impact factor: 1.475

10.  Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial.

Authors:  Didier Frappaz; Matthias Schell; Philippe Thiesse; Perrine Marec-Bérard; Carmine Mottolese; David Perol; Christophe Bergeron; Thierry Philip; Anne Claire Ricci; Sophie Galand-Desme; Alexandru Szathmari; Christian Carrie
Journal:  Neuro Oncol       Date:  2008-06-24       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.